Luye Pharma USA is showcasing Erzofri at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Erzofri is the first Chinese-developed paliperidone palmitate LAI approved in the US — directly competing with J&J's Invega Sustenna. At APA, they'll emphasize pricing/access advantages and clinical equivalence. LAI adherence is a hot topic for psychiatrists managing schizophrenia.
Ask about: Pricing vs. Invega Sustenna; formulary wins and payer traction; clinical equivalence data; manufacturing/supply chain reliability. The value conversation is straightforward — same molecule, potentially better access.
ePRO+ captures between-injection symptom outcomes and adherence data — supports RWE generation that proves Erzofri delivers equivalent outcomes at better value. VoiceVitals for continuous schizophrenia symptom monitoring between monthly injections.
Set up a follow-up with Luye Pharma USA's team and Videra Health.
Email Ryan Roberts →